Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transgene Biotek, an Indian firm, has sold its technology for recombinant human Erythropoietin (rh-EPO) for $5m, to TSS Export GmbH FZE, a subsidiary of the German TSS Group.
Subscribe to our email newsletter
According to the company, the transaction is expected to close in a span of five or six months.
Transgene Biotek managing director KK Rao said the deal would help the company lay emphasis on monetising the sale of underutilised bio-generic drug assets.
The company is currently manufacturing DHA, an Omega-3 Fatty acid used in the nutraceuticals and health supplements market.
Transgene is also developing APIs (active pharma ingredients) and is likely to begin the production of a second API, Tacrolimus.